Author Archives: Marylyn Donahue

The Baltic States: A Location for Your Next Clinical Trial

The Baltic States with its appropriate population size, sufficient infrastructure, and experienced and motivated investigators, make it an attractive choice for a clinical trial. In this article, Doatas Grina, Indre Tutlyte and Auudius Sveikata, PhD, that ran in the February 2013 issue of Applied Clinical Trials, presents a persuasive case for the area’s present desirability as well as […]
Posted in Europe, Global, R&D | Tagged , | Leave a comment

Are You Aging Well? Ask Pfizer

I’ve just finished taking Pfizer’s #FOGO (Have A Fear of Getting Old?) test on getold.com. I passed with flying colors. The results assured me that I would have a hell of a time aging during these advancing years and that the last lap of my life would be a breeze. Why? I wonder. Was it […]
Posted in healthcare, Op-Ed, Patient Communication, patient education, social media | Tagged , , | Leave a comment

Suffer Little Children? To Medicate or Not to Medicate Toddlers

When Audre McDonald accepted her sixth Tony Award (theater’s version of the Academy Awards) this month in New York City, and broadcast live on national television, she thanked her parents “for their unwillingness to put her on stimulant medication, which she believed led to her stunning success in musical theater.” In the aftermath, her comments […]
Posted in FDA, Global, healthcare | Tagged , , , , , | Leave a comment

High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]
Posted in healthcare, pricing | Tagged , , | 1 Comment

Is Gilead’s $1000 Pill Worth It?

The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants. What should the patients of “milder” cases do then? Twiddle their thumbs and wait for drugs in […]
Posted in pricing, Regulatory | Tagged , , , , | 2 Comments
  • Categories

  • Meta